Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Total Non-Current Liabilities (2016 - 2023)

Alaunos Therapeutics (TCRT) has disclosed Total Non-Current Liabilities for 11 consecutive years, with $2.0 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Total Non-Current Liabilities fell 92.58% year-over-year to $2.0 million, compared with a TTM value of $2.0 million through Dec 2023, down 92.58%, and an annual FY2023 reading of $2.0 million, down 92.58% over the prior year.
  • Total Non-Current Liabilities was $2.0 million for Q4 2023 at Alaunos Therapeutics, down from $5.5 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $36.8 million in Q4 2021 and bottomed at $2.0 million in Q4 2023.
  • Average Total Non-Current Liabilities over 3 years is $20.6 million, with a median of $22.7 million recorded in 2022.
  • The sharpest move saw Total Non-Current Liabilities decreased 28.4% in 2022, then plummeted 92.58% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $36.8 million in 2021, then fell by 28.4% to $26.4 million in 2022, then tumbled by 92.58% to $2.0 million in 2023.
  • Business Quant data shows Total Non-Current Liabilities for TCRT at $2.0 million in Q4 2023, $5.5 million in Q3 2023, and $6.3 million in Q2 2023.